Complementary therapies for treating irritable bowel syndrome with constipation include exercise, probiotics, peppermint oil supplements, soluble dietary fiber, and gut-directed mental health ...

Findings showed 30% of patients taking linaclotide 145mcg achieved the primary endpoint of combined responder. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the ...

For millions of Americans, bathroom trips bring anxiety rather than relief. Irritable bowel syndrome with constipation (IBS-C) impacts approximately one-third of all IBS cases, causing physical ...

Learn why the gut–brain connection increases stress and affects IBS symptoms and explore evidence-based treatments like gut-directed hypnotherapy, CBT, mindfulness, and exercise to help break the ...

WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

A study recently published in Gastroenterology presents a possible breakthrough in the treatment of irritable bowel syndrome. According to a June 5 news release, the trial included 238 patients across ...

Approximately 2% of patients with irritable bowel syndrome (IBS) have a mutation of the SCN5A gene that disrupts sodium channel function, according to a genotype analysis published online March 10 in ...

A low-FODMAP diet is recommended for many people with IBS-C to help prevent flare-ups. Increasing soluble fiber may ease symptoms by making stool softer and easier to pass. Over-the-counter laxatives ...

WALTHAM, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Ardelyx introduced Ibsrela into the well-established IBS-C market and implemented its strategy to attain consistent market. The prolonged absence of effective treatment choices for IBS-C patients ...